Many types of cancer are currently untreatable. In Canada alone, 78,000 cancer-related deaths are seen annually, and obviously, new therapies are needed. We have identified the protein PARG as a potent stimulator of cancer growth and a valid target for anti-cancer therapy. However, specific, cell permeable inhibitors of PARG have historically been difficult to generate. Thus, PARG inhibitors have not yet reached the market nor even clinical trials. Towards this goal we have initiated a project to identify drugs to inhibit PARG.